title: [Cardiovascular protection and prevention in patients with cardiac conditions and diabetes].
abstract: Good glycemic control can have a positive effect on the course and prognosis of coronary disease during and after myocardial infarction. It also reduces the risk of its onset. Both postprandial and fasting blood glucose must be normalized. Optimal treatment of coronary patients should include reduction of risk factors and 4 drugs: a beta-blocker at an effectively beta-blocking dose, aspirin at a daily dose between 75 and 100 mg, a statin that leads to an LDL-cholesterol level less than 1 g/L, and an angiotensin-converting enzyme inhibitor, with a demonstrated dose-effect relation. Efficacy is best when compliance is considered an essential objective.
authors.affiliation: Service de diabétologie, CH Sud Francilien, Corbeil (91). guillaume.charpentier@ch ncilien.fr
authors.forename: G
authors.initials: G
authors.lastname: Charpentier
authors.forename: J
authors.initials: J
authors.lastname: Puel
authors.forename: P-G
authors.initials: PG
authors.lastname: Steg
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010349:Patient Compliance; D010919:Placebos; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001241:Aspirin; D001786:Blood Glucose; D008078:Cholesterol, LDL; D006442:Glycated Hemoglobin; D000960:Hypolipidemic Agents; D010919:Placebos; D010975:Platelet Aggregation Inhibitors